Dimensional Fund Advisors LP Grows Position in Replimune Group, Inc. (NASDAQ:REPL)

Dimensional Fund Advisors LP boosted its holdings in shares of Replimune Group, Inc. (NASDAQ:REPL - Free Report) by 42.7% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm owned 778,163 shares of the company's stock after buying an additional 232,822 shares during the period. Dimensional Fund Advisors LP owned approximately 1.14% of Replimune Group worth $9,425,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also bought and sold shares of the company. Vanguard Group Inc. increased its holdings in shares of Replimune Group by 3.7% during the fourth quarter. Vanguard Group Inc. now owns 3,595,848 shares of the company's stock valued at $43,546,000 after acquiring an additional 129,601 shares in the last quarter. Wellington Management Group LLP grew its stake in shares of Replimune Group by 352.5% during the fourth quarter. Wellington Management Group LLP now owns 1,096,744 shares of the company's stock worth $13,282,000 after acquiring an additional 854,346 shares during the last quarter. Marshall Wace LLP acquired a new position in shares of Replimune Group in the 4th quarter valued at about $10,853,000. Artisan Partners Limited Partnership purchased a new position in Replimune Group during the fourth quarter worth approximately $7,399,000. Finally, Charles Schwab Investment Management Inc. raised its position in Replimune Group by 4.9% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 508,398 shares of the company's stock valued at $6,157,000 after purchasing an additional 23,601 shares during the period. 92.53% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on REPL. HC Wainwright upped their target price on Replimune Group from $21.00 to $22.00 and gave the company a "buy" rating in a research note on Thursday, February 13th. JPMorgan Chase & Co. increased their price target on Replimune Group from $16.00 to $18.00 and gave the company an "overweight" rating in a report on Wednesday, February 26th. Finally, BMO Capital Markets lifted their price target on Replimune Group from $18.00 to $27.00 and gave the company an "outperform" rating in a report on Wednesday, January 22nd. Seven analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Buy" and an average target price of $19.43.

Replimune Group Stock Performance

NASDAQ REPL traded up $0.01 on Thursday, reaching $7.02. 179,661 shares of the company's stock traded hands, compared to its average volume of 897,975. Replimune Group, Inc. has a fifty-two week low of $4.92 and a fifty-two week high of $17.00. The stock has a 50 day moving average price of $9.10 and a 200-day moving average price of $11.39. The company has a debt-to-equity ratio of 0.14, a quick ratio of 11.43 and a current ratio of 11.43. The firm has a market cap of $540.65 million, a price-to-earnings ratio of -2.29 and a beta of 0.68.

Replimune Group (NASDAQ:REPL - Get Free Report) last released its quarterly earnings results on Wednesday, February 12th. The company reported ($0.79) EPS for the quarter, missing the consensus estimate of ($0.70) by ($0.09). Equities research analysts predict that Replimune Group, Inc. will post -2.97 EPS for the current fiscal year.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.